JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

Search

Crinetics Pharmaceuticals Inc

Abrir

SetorSaúde

38.78 -0.64

Visão Geral

Variação de preço das ações

24h

Atual

Mín

38.08

Máximo

39.13

Indicadores-chave

By Trading Economics

Rendimento

7.3M

-123M

Vendas

3.7M

3.9M

EPS

-1.29

Margem de lucro

-3,161.261

Funcionários

594

EBITDA

20M

-122M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+122.9% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-275M

4.2B

Abertura anterior

39.42

Fecho anterior

38.78

Sentimento de Notícias

By Acuity

39%

61%

152 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2026, 00:00 UTC

Notícias Principais

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 de abr. de 2026, 23:33 UTC

Ganhos

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 de abr. de 2026, 22:40 UTC

Ganhos

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 de abr. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:11 UTC

Ganhos

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 de abr. de 2026, 21:01 UTC

Ganhos

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 de abr. de 2026, 23:16 UTC

Ganhos

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 de abr. de 2026, 23:15 UTC

Ganhos

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 de abr. de 2026, 22:52 UTC

Ganhos

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 de abr. de 2026, 22:51 UTC

Ganhos

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 de abr. de 2026, 22:29 UTC

Ganhos

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 de abr. de 2026, 22:27 UTC

Ganhos

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 de abr. de 2026, 22:06 UTC

Conversa de Mercado
Ganhos

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:47 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:37 UTC

Ganhos

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 de abr. de 2026, 21:34 UTC

Ganhos

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 de abr. de 2026, 21:29 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:20 UTC

Conversa de Mercado
Ganhos

Tesla Expands Manufacturing to Chips -- Market Talk

Comparação entre Pares

Variação de preço

Crinetics Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

122.9% parte superior

Previsão para 12 meses

Média 86.71 USD  122.9%

Máximo 97 USD

Mínimo 67 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

8

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

30.39 / 33.46Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

152 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat